ArticleJournal of fungi (Basel, Switzerland)2021
In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents.
Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Management, Outcomes, and Factors Associated With Mortality and Treatment Failure of Non-Open forum infectious diseases · 2026Article
- Multicenter surveillance of antifungal susceptibility of clinicalMicrobiology spectrum · 2026Article
- Invasive aspergillosis in lung and heart transplant recipients.JHLT open · 2026Article
- Genomic Insights ofOpen forum infectious diseases · 2026Review
- Prevalence and diversity of antifungal resistance inAntimicrobial agents and chemotherapy · 2025Article
- Olorofim activity against multidrug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Endemic Mycoses for Pulmonary Clinicians: From Nodules to ARDS.CHEST pulmonary · 2025Review
- Article
- Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds.The Journal of antimicrobial chemotherapy · 2025Review
- Olorofim demonstratesAntimicrobial agents and chemotherapy · 2025Article
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.Clinical microbiology reviews · 2024Review
- The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies.Journal of fungi (Basel, Switzerland) · 2024Review
- Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.Frontiers in microbiology · 2024Review
- Refractory Microascus Bronchopulmonary Infection Treated with Olorofim, France.Emerging infectious diseases · 2023Article
- Treatment of Invasive Aspergillosis: How It's Going, Where It's Heading.Mycopathologia · 2023Review
- [Anti-infective treatment of fungal infections by Candida and Aspergillus].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olorofim is a novel antifungal drug that belongs to the orotomide drug class which inhibits fungal dihydroorotate dehydrogenase (DHODH), thus halting pyrimidine biosynthesis and ultimately DNA synthesis, cell growth and division. It is being developed at a time when many invasive fungal infections exhibit antifungal resistance or have limited treatment options. The goal of this study was to evaluate the in vitro effectiveness of olorofim against a large collection of recently isolated, clinically relevant American mold isolates. In vitro antifungal activity was determined for 246 azole-susceptible
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.